Mortality risk with sulphonylureas compared to metformin.
Diabetes Obes Metab
; 16(10): 885-90, 2014 Oct.
Article
en En
| MEDLINE
| ID: mdl-24533964
ABSTRACT
Current clinical guidelines in the USA and the UK recommend first-line glucose-lowering treatment with metformin monotherapy for glucose control in type 2 diabetes, where not contraindicated. Consequently, the proportion of people treated with sulphonylureas is decreasing. The purpose of this commentary is to discuss the risks and benefits associated with sulphonylurea monotherapy versus metformin monotherapy and the evidence that, in comparison with metformin, sulphonylureas cause increased harm to people with type 2 diabetes.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Compuestos de Sulfonilurea
/
Diabetes Mellitus Tipo 2
/
Hipoglucemiantes
/
Metformina
Tipo de estudio:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Límite:
Humans
País como asunto:
America do norte
Idioma:
En
Año:
2014
Tipo del documento:
Article